VERTEX PHARMACEUTICALS INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 473.7 USD | -1.46% |
|
-1.98% | +16.42% |
| 06-17 | Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465 | MT |
| 06-14 | Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials | MT |
Presenter SpeechMyles Minter (Analysts)All right. Thank you very much. Welcome back to the Wil...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Calendar
31/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
473.7
USD
Average target price
463.4
USD
Spread / Average Target
-2.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.42% | 122B | |
| +19.02% | 113B | |
| +3.14% | 22.66B | |
| -16.20% | 21.34B | |
| -39.57% | 16.92B | |
| -11.63% | 16.68B | |
| -16.15% | 16.61B | |
| +2.68% | 13.62B | |
| +21.16% | 11.04B | |
| +108.78% | 10.43B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Transcript : Vertex Pharmaceuticals Incorporated Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 04
